CROSSJECT News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.12.24	Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M (GlobeNewswire)
10.12.24	Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m (GlobeNewswire)
09.12.24	Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement (GlobeNewswire)
13.11.24	Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions (GlobeNewswire)
22.10.24	Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization (GlobeNewswire)
26.09.24	Crossject announces its eligibility for France’s PEA-PME investment scheme (GlobeNewswire)
23.09.24	Crossject reports financial results and business highlights for the first six months of 2024 (GlobeNewswire)
17.09.24	Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 (GlobeNewswire)
22.08.24	Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 (GlobeNewswire)
19.08.24	Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment (GlobeNewswire)
18.07.24	Crossject achieves key ZEPIZURE® manufacturing milestone (GlobeNewswire)
15.07.24	Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
10.07.24	Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine (GlobeNewswire)
26.06.24	Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study (GlobeNewswire)
12.06.24	Crossject appoints Dan Chiche, MD as Chief Medical Officer North America (GlobeNewswire)
04.06.24	Crossject announces highly successful closing of its €8 million rights offering (GlobeNewswire)
30.05.24	Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy (GlobeNewswire)
02.05.24	Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe (GlobeNewswire)
25.04.24	Crossject reports audited financial results for 2023 (GlobeNewswire)
02.04.24	Crossject trading on Euronext to resume as usual on Wednesday April 3 (GlobeNewswire)
02.04.24	Crossject advances in its U.S. Strategy and reports Financial Results for 2023 (GlobeNewswire)
08.03.24	Crossject gender equality score reaches 96/100 in 2024 (GlobeNewswire)
27.02.24	Crossject obtains a financing up to €12 million, in two tranches (GlobeNewswire)
06.02.24	Crossject provides strategic update on priorities for 2024 (GlobeNewswire)
01.02.24	Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET (GlobeNewswire)
09.01.24	Crossject to present at Biotech Showcase on January 9 at 16:30 PT (GlobeNewswire)
04.01.24	Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® (GlobeNewswire)
22.12.23	Crossject signs ZEPIZURE® commercialization agreement for northern Europe (GlobeNewswire)
28.11.23	Crossject announces initiation of coverage by ODDO BHF (GlobeNewswire)
26.09.23	Crossject reports financial results and business highlights for first half of 2023 (GlobeNewswire)
11.09.23	Crossject announces significant improvement in Gaïa ESG rating (GlobeNewswire)
05.09.23	Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures (GlobeNewswire)
20.07.23	Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand (GlobeNewswire)
01.06.23	Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition (GlobeNewswire)
21.03.23	Crossject - 2022 Annual Results (GlobeNewswire)
20.03.23	CROSSJECT - 2022 Annual Results (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	133.55	4.50 %	K V
Swiss Life Hldg	693.60	0.93 %	K V
Zurich Insur Gr	552.80	0.91 %	K V
Kuehne+Nagel Int	206.60	0.78 %	K V
Sonova Hldg	294.00	0.58 %	K V
Sika	228.20	-1.04 %	K V
Part Grp Hldg	1’264.50	-1.56 %	K V
Geberit	538.20	-1.61 %	K V
Alcon	75.22	-1.75 %	K V
Lonza Grp	532.80	-2.81 %	K V

Nachrichten zu CROSSJECT

Aktien Top/Flop

Meistgelesene Nachrichten